109 related articles for article (PubMed ID: 9853809)
1. First experience with the REMEDi HS urine benzodiazepine assay.
Musshoff F; Madea B
Clin Chem Lab Med; 1998 Oct; 36(10):803-8. PubMed ID: 9853809
[TBL] [Abstract][Full Text] [Related]
2. Identification of urinary benzodiazepines and their metabolites: comparison of automated HPLC and GC-MS after immunoassay screening of clinical specimens.
Valentine JL; Middleton R; Sparks C
J Anal Toxicol; 1996 Oct; 20(6):416-24. PubMed ID: 8889678
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the REMEDi drug profiling system.
Demedts P; Wauters A; Franck F; Neels H
Eur J Clin Chem Clin Biochem; 1994 May; 32(5):409-17. PubMed ID: 8086525
[TBL] [Abstract][Full Text] [Related]
4. Determination of benzodiazepines in clinical serum samples: comparative evaluation of REMEDi system, aca analyzer, and conventional HPLC performance.
Chang TL; Chen KW; Lee YD; Fan K
J Clin Lab Anal; 1999; 13(3):106-11. PubMed ID: 10323474
[TBL] [Abstract][Full Text] [Related]
5. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
Darragh A; Snyder ML; Ptolemy AS; Melanson S
Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine.
DeRienz RT; Holler JM; Manos ME; Jemionek J; Past MR
J Anal Toxicol; 2008; 32(6):433-7. PubMed ID: 18652750
[TBL] [Abstract][Full Text] [Related]
7. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
Dixon RB; Floyd D; Dasgupta A
Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
[TBL] [Abstract][Full Text] [Related]
8. Automated liquid-chromatographic analyzer used for toxicology screening in a general hospital: 12 months' experience.
Sadeg N; François G; Petit B; Dutertre-Catella H; Dumontet M
Clin Chem; 1997 Mar; 43(3):498-504. PubMed ID: 9068594
[TBL] [Abstract][Full Text] [Related]
9. Disopyramide analysis using REMEDi: comparison with EMIT and conventional high performance liquid chromatographic methods.
Patel V; McCarthy PT; Flanagan RJ
Biomed Chromatogr; 1991 Nov; 5(6):269-72. PubMed ID: 1760593
[TBL] [Abstract][Full Text] [Related]
10. Use of direct-probe mass spectrometry as a toxicology confirmation method for demoxepam in urine following high-performance liquid chromatography.
Essien H; Lai SJ; Binder SR; King DL
J Chromatogr B Biomed Appl; 1996 Aug; 683(2):199-208. PubMed ID: 8891916
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of an immunological new kit used in the toxicological screening of benzodiazepines in hospital emergency care units].
Zorza G; Brun-Ney D; Delhotal Landes B; Flouvat B
Ann Biol Clin (Paris); 1994; 52(5):347-53. PubMed ID: 7856934
[TBL] [Abstract][Full Text] [Related]
12. Toxicological screening in urine: comparison of two automated HPLC screening systems, toxicological identification system (TOX.I.S.*) versus REMEDI-HS.
Schönberg L; Grobosch T; Lampe D; Kloft C
J Anal Toxicol; 2007; 31(6):321-7. PubMed ID: 17725877
[TBL] [Abstract][Full Text] [Related]
13. Urinary screening for benzodiazepines with radioreceptor assay: comparison with EMIT d.a.u. benzodiazepine assay and high-performance liquid chromatography.
Borggaard B; Joergensen I
J Anal Toxicol; 1994 Sep; 18(5):243-6. PubMed ID: 7990439
[TBL] [Abstract][Full Text] [Related]
14. LC-(TOF) MS analysis of benzodiazepines in urine from alleged victims of drug-facilitated sexual assault.
ElSohly MA; Gul W; Murphy TP; Avula B; Khan IA
J Anal Toxicol; 2007 Oct; 31(8):505-14. PubMed ID: 17988465
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive drug screening by integrated use of gas chromatography/mass spectrometry and Remedi HS.
Valli A; Polettini A; Papa P; Montagna M
Ther Drug Monit; 2001 Jun; 23(3):287-94. PubMed ID: 11360040
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
Manchikanti L; Malla Y; Wargo BW; Fellows B
Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of four immunoassay screening devices for detection of benzodiazepine and its metabolites in urine: mainly detection of etizolam, thienodiazepine and its metabolites].
Namera A; Makita R; Nagao M
Chudoku Kenkyu; 2011 Mar; 24(1):27-34. PubMed ID: 21485120
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Two Immunoassay Screening Methods and a LC-MS/MS in Detecting Traditional and Designer Benzodiazepines in Urine.
Rossi B; Freni F; Vignali C; Stramesi C; Collo G; Carelli C; Moretti M; Galatone D; Morini L
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011344
[TBL] [Abstract][Full Text] [Related]
19. Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT d.a.u. benzodiazepine metabolite assay.
Fraser AD
J Anal Toxicol; 1987; 11(6):263-6. PubMed ID: 3323671
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunoassay screening tests and LC-MS-MS for urine detection of benzodiazepines and their metabolites: results of a national proficiency test.
Bertol E; Vaiano F; Borsotti M; Quercioli M; Mari F
J Anal Toxicol; 2013; 37(9):659-64. PubMed ID: 23943436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
